Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Position Decreased by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC lowered its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 21.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 76,698 shares of the medical research company's stock after selling 20,844 shares during the quarter. Anchor Capital Advisors LLC owned 0.26% of Bio-Rad Laboratories worth $24,765,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. GAMMA Investing LLC acquired a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth about $42,000. ING Groep NV purchased a new position in Bio-Rad Laboratories during the third quarter worth about $44,000. Bfsg LLC acquired a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at about $77,000. Signaturefd LLC increased its position in shares of Bio-Rad Laboratories by 15.8% during the fourth quarter. Signaturefd LLC now owns 352 shares of the medical research company's stock valued at $114,000 after acquiring an additional 48 shares during the last quarter. Finally, Banque Cantonale Vaudoise raised its stake in shares of Bio-Rad Laboratories by 25.0% in the 3rd quarter. Banque Cantonale Vaudoise now owns 375 shares of the medical research company's stock valued at $135,000 after acquiring an additional 75 shares during the period. Hedge funds and other institutional investors own 65.24% of the company's stock.

Insider Transactions at Bio-Rad Laboratories

In related news, EVP Michael Crowley sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total value of $1,008,000.00. Following the sale, the executive vice president now owns 6,942 shares of the company's stock, valued at $2,332,512. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 17.50% of the company's stock.

Bio-Rad Laboratories Stock Up 0.4 %

Shares of NYSE:BIO traded up $1.01 during trading on Monday, hitting $276.96. The company's stock had a trading volume of 154,843 shares, compared to its average volume of 202,359. Bio-Rad Laboratories, Inc. has a fifty-two week low of $261.59 and a fifty-two week high of $473.50. The business has a 50 day moving average price of $323.67 and a two-hundred day moving average price of $316.47. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.34 and a current ratio of 5.83. The company has a market capitalization of $7.90 billion, a PE ratio of -12.89 and a beta of 0.87.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Thursday, February 15th. The medical research company reported $3.10 EPS for the quarter, topping the consensus estimate of $2.93 by $0.17. The firm had revenue of $681.18 million during the quarter, compared to analysts' expectations of $685.00 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. Bio-Rad Laboratories's revenue for the quarter was down 6.7% on a year-over-year basis. During the same period in the previous year, the firm posted $3.31 EPS. As a group, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Royal Bank of Canada lowered their price objective on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an "outperform" rating for the company in a research report on Friday, February 16th. Citigroup lowered Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $400.00 to $365.00 in a research report on Wednesday, April 3rd. UBS Group boosted their price objective on Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a "buy" rating in a report on Friday, February 16th. Finally, StockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Thursday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $468.00.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.